Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)

NCT01966107 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT01966107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01966107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase IV Study to Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and COPD Exacerbations in Patients With Moderate to Very Severe COPD (ASCENT COPD)
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Completed
Start date
October 16, 2013
Completion date
September 21, 2017
Enrollment
3,635 (actual)
Sites
468

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd, moderate to very severe copd